A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Male and/or female subjects between the ages of 18 and 60 years;

• Body Mass Index (BMI) of >25.0 kg/m2 and <40 kg/m2;

• Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines;

• Subjects who have been on well-tolerated and stable doses of metformin

Exclusion Criteria:

• Recent evidence (6 months prior to screening) or history of unstable major organ disease;

• Diagnosis of Type 1 diabetes mellitus;

• Current medical history of myocardial infarction, unstable angina, or history of stroke (including TIA) within 6 months prior to Screening;

• Treatment with thiazolidinediones (TZDs), or subcutaneously administered antidiabetic agents;